An in vitro test for teratogens: its practical application

Area of Science:

• Developmental toxicology
• Pharmacology
• Cell biology

Background:

• Teratogens pose risks during pharmaceutical development.
• Accurate in vitro testing is crucial for early identification of teratogenic compounds.
• Existing methods require refinement for improved predictive power.

Purpose of the Study:

• To validate and describe an established in vitro teratogen test for early pharmaceutical evaluation.
• To assess the predictive accuracy and practical application of the rat embryo cell differentiation assay.
• To investigate the role of maternal metabolism activation in teratogenicity testing.

Main Methods:

• Exposure of undifferentiated rat embryo midbrain and limb cells to test compounds.
• Observation of effects on subsequent cell differentiation.
• Incorporation of Aroclor 1254-induced rat liver homogenate (S-9 mix) to model maternal metabolism.

Main Results:

• The in vitro test demonstrated over 90% accuracy in predicting teratogens, confirmed by extensive use.
• The assay is routinely employed in early drug development, testing approximately 250 compounds annually.
• Reduced S-9 mix concentrations (3-5 µl/ml) activated pro-teratogens without toxicity to embryo cells.

Conclusions:

• The validated in vitro teratogen test is a reliable tool for selecting non-teratogenic pharmaceuticals.
• The study highlights the importance of optimized S-9 mix concentrations for activating pro-teratogens.
• Evidence suggests potential drug-metabolizing activity within embryonic cells, warranting further investigation.